Amol Akhade: Datopotomab deruxtecan got approved for HR+ HER2- MBC in the third line
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“Datopotomab deruxtecan got approved for HR-positive HER2 negative (low and ultra-low included) MBC in the third line. Tropion breast 01 had no OS benifit.
PFS curves were well separated.
How will we sequence it?
Will it work after trastuzumab deruxtecan is the main question?”
More posts featuring Amol Akhade.
Amol Akhade is a Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics. He is also a Senior Consultant Medical Oncologist and Hemato-oncologist at Reliance Hospitals, Bombay Hospital and Research Center and Hiranandani Hospital.
He has received his specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplants.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023